Tags

Type your tag names separated by a space and hit enter

Triple therapies plus different probiotics for Helicobacter pylori eradication.
Eur Rev Med Pharmacol Sci 2008 Jul-Aug; 12(4):251-6ER

Abstract

The Helicobacter pylori (H. pylori) cure rate following standard triple therapies is decreasing worldwide. Therefore, further approaches aimed to improve standard triple therapy efficacy should be attempted. This prospective, pilot study aimed to evaluate the therapeutic role of either Lactobacillus reuteri (L. reuteri) or a high concentration of probiotics in addition to standard triple therapies for H. pylori eradication. The study enrolled 65 consecutive dyspeptic patients with H. pylori infection. All patients underwent upper endoscopy with gastric biopsies. Patients were assigned to receive one of the following therapies: (a) standard 7-day triple; (b) the same 7-day triple therapy plus L. reuteri supplementation; (c) the same 7-day triple therapy plus a probiotic mixture; and d) a 14-day standard triple therapy plus a probiotic mixture. H. pylori eradication was checked by using a 13C-urea breath test performed 4-6 weeks after treatment. No therapy regimen achieved > 80% eradication rate at both intention-to-treat (ITT) and per protocol (PP) analyses. Although the 14-day therapy plus a probiotic mixture tended to achieve higher eradication rate (71%), no statistically significant difference emerged among the different therapy regimens tested (range: 53-71%). The lowest incidence of side-effects was observed following the 7-day therapy plus L. reuteri (6%) and highest with the 14-day triple therapy plus probiotic mixture (33%), although the difference failed to reach the statistically significance. In conclusion, our data found that 7-14 days triple therapy with or without probiotic supplementation failed to achieved acceptable H. pylori eradication rates.

Authors+Show Affiliations

Digestive Endoscopy, Umberto I Hospital, Altamura, Bari, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

18727457

Citation

Scaccianoce, G, et al. "Triple Therapies Plus Different Probiotics for Helicobacter Pylori Eradication." European Review for Medical and Pharmacological Sciences, vol. 12, no. 4, 2008, pp. 251-6.
Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 2008;12(4):251-6.
Scaccianoce, G., Zullo, A., Hassan, C., Gentili, F., Cristofari, F., Cardinale, V., ... Morini, S. (2008). Triple therapies plus different probiotics for Helicobacter pylori eradication. European Review for Medical and Pharmacological Sciences, 12(4), pp. 251-6.
Scaccianoce G, et al. Triple Therapies Plus Different Probiotics for Helicobacter Pylori Eradication. Eur Rev Med Pharmacol Sci. 2008;12(4):251-6. PubMed PMID: 18727457.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Triple therapies plus different probiotics for Helicobacter pylori eradication. AU - Scaccianoce,G, AU - Zullo,A, AU - Hassan,C, AU - Gentili,F, AU - Cristofari,F, AU - Cardinale,V, AU - Gigliotti,F, AU - Piglionica,D, AU - Morini,S, PY - 2008/8/30/pubmed PY - 2008/9/26/medline PY - 2008/8/30/entrez SP - 251 EP - 6 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 12 IS - 4 N2 - The Helicobacter pylori (H. pylori) cure rate following standard triple therapies is decreasing worldwide. Therefore, further approaches aimed to improve standard triple therapy efficacy should be attempted. This prospective, pilot study aimed to evaluate the therapeutic role of either Lactobacillus reuteri (L. reuteri) or a high concentration of probiotics in addition to standard triple therapies for H. pylori eradication. The study enrolled 65 consecutive dyspeptic patients with H. pylori infection. All patients underwent upper endoscopy with gastric biopsies. Patients were assigned to receive one of the following therapies: (a) standard 7-day triple; (b) the same 7-day triple therapy plus L. reuteri supplementation; (c) the same 7-day triple therapy plus a probiotic mixture; and d) a 14-day standard triple therapy plus a probiotic mixture. H. pylori eradication was checked by using a 13C-urea breath test performed 4-6 weeks after treatment. No therapy regimen achieved > 80% eradication rate at both intention-to-treat (ITT) and per protocol (PP) analyses. Although the 14-day therapy plus a probiotic mixture tended to achieve higher eradication rate (71%), no statistically significant difference emerged among the different therapy regimens tested (range: 53-71%). The lowest incidence of side-effects was observed following the 7-day therapy plus L. reuteri (6%) and highest with the 14-day triple therapy plus probiotic mixture (33%), although the difference failed to reach the statistically significance. In conclusion, our data found that 7-14 days triple therapy with or without probiotic supplementation failed to achieved acceptable H. pylori eradication rates. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/18727457/Triple_therapies_plus_different_probiotics_for_Helicobacter_pylori_eradication_ L2 - https://medlineplus.gov/helicobacterpyloriinfections.html DB - PRIME DP - Unbound Medicine ER -